Genome-based pharmacogenetics and the pharmaceutical industry.
Pharmacogenetic capabilities have changed markedly since The SNP Consortium made a dense single-nucleotide polymorphism (SNP) map freely available in 2001. For more than 40 years, pharmacokinetics and pharmacodynamics of drug-metabolizing molecules were the focus of practical applications. Today, it is possible to use SNP-mapping technologies to create a genetic profile of each individual that can be used to identify patterns of susceptibility genes for common diseases as well as genetic risk/efficacy factors that are related to the effects of drugs.
Roses
Allen D
AD
GlaxoSmithKline, Five Moore Drive, Research Triangle Park, North Carolina 27709, USA. adr69412@gsk.com
D002986:Clinical Trials as Topic; D015224:Dideoxynucleosides / Q000009:adverse effects; D004345:Drug Industry; D020022:Genetic Predisposition to Disease; D016678:Genome; D006801:Humans; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D020543:Proteome; D000099227:Abacavir
D015224:Dideoxynucleosides; D020543:Proteome; D000099227:Abacavir